Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

Expert Review of Vaccines

Volumn 15, Issue 4, 2016, Pages 437-441

  Wilder Smith, Annelies ^a   Massad, Eduardo ^b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

age indication; dengue; efficacy; vaccine

Indexed keywords

DENGUE VACCINE; CYD-TDV VACCINE; VIRUS ANTIBODY;

AGE; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; DENGUE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SECONDARY INFECTION; VACCINATION; ADOLESCENT; ADULT; BLOOD; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958551392     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1143366     Document Type: Article

References (22)

1. Monath TP, Seligman SJ, Robertson JS, et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015; 33 (1): 62-72.
2. Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013; 31 (41): 4501-4507.
3. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384 (9951): 1358-1365.
4. Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372 (2): 113-123.
5. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195-1206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.
6. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380 (9853): 1559-1567.
7. Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011; 29 (42): 7229-7241.
8. Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014; 384 (9951): 1327-1329.
9. Gubler D. 70 years on: progress in dengue vaccine development. Vaccine Companion. 2011; 4: 1-3.
10. Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012; 8 (9): 1259-1271.
11. Dorigatti I, Aguas R, Donnelly CA, et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015; 33 (31): 3746-3751.
12. Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014; 209 (3): 360-368.
13. Guzmán MG, Kourí G, Valdés L, et al. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002; 11 (4): 223-227.
14. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386 (9988): 31-45.
15. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013; 5: 299-309.
16. Limkittikul K, Brett J, LAzou M. Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. PLoS Negl Trop Dis. 2014; 8 (11): e3241.
17. Teixeira MG, Siqueira JB Jr, Ferreira GL, et al. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013; 7 (12): e2520.
18. SISTEMA DE INFORMAÇÃO DE AGRAVOS DE NOTIFICAÇÃO-SINAN. [Internet]. 2015. [cited 2015 Oct 7]. Available from: http://dtr2004.saude.gov.br/sinanweb/.
19. Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine. 2014; 32 (26): 3133-3138.
20. Kelly H, Attia J, Andrews R, et al. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine. 2004; 22 (17-18): 2192-2198.
21. Wilder-Smith A, Gubler DJ. Public health. Dengue vaccines at a crossroad. Science. 2015; 350 (6261): 626-627.
22. SAGE Working Group on Dengue Vaccines and Vaccination. [Internet]. 2015. [cited 2015 Oct 7]. Available from: http://www.who.int/immunization/policy/sage/sage-wg-dengue-mar2015/en/.